Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on AstraZeneca plc (LON:AZN) in a research note issued to investors on Tuesday. The brokerage currently has a a sell rating on the biopharmaceutical company’s stock.
Several other analysts have also issued reports on the company. Bryan, Garnier & Co reiterated a buy rating on shares of AstraZeneca plc in a report on Thursday, July 28th. Morgan Stanley reissued an overweight rating and set a GBX 5,000 ($65.27) target price on shares of AstraZeneca plc in a research report on Monday, July 11th. Credit Suisse Group AG reissued an underperform rating and set a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc in a research report on Monday, June 27th. Jefferies Group increased their target price on shares of AstraZeneca plc from GBX 4,100 ($53.52) to GBX 4,450 ($58.09) and gave the stock a hold rating in a research report on Thursday, June 30th. Finally, BNP Paribas set a GBX 5,300 ($69.18) target price on shares of AstraZeneca plc and gave the stock a buy rating in a research report on Tuesday, August 2nd. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 5087.00 on Tuesday. The company’s 50-day moving average price is GBX 5,004.64 and its 200 day moving average price is GBX 4,431.30. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s market cap is GBX 64.35 billion.
The business also recently declared a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were issued a GBX 68.70 ($0.90) dividend. This represents a dividend yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.